

ARMED WITH PROPEL

PROPEL®  
MOMETASONE FUROATE SINUS IMPLANTS

## PROPEL releases mometasone furoate= Your localized drug delivery treatment for improved postsurgical outcomes



### OPENS + DELIVERS

PROPEL implants feature an innovative **2-in-1 mechanism** that keeps the sinuses open while **delivering mometasone furoate**, a potent and targeted corticosteroid, which readily absorbs into tissue with limited systemic absorption<sup>1-3</sup>

Explore how PROPEL can improve postsurgical outcomes in your patients at [PROPELOpens.com](https://PROPELOpens.com)

 **intersect**  
ENT

# MOMETASONE FUROATE DELIVERS THE IDEAL COMBINATION OF POTENCY + SAFETY

+ Intersect ENT specifically selected mometasone furoate in the PROPEL implants for its optimal drug characteristics<sup>4-6</sup>



**Highly lipophilic**  
Readily absorbs into tissue



**Targeted + potent**  
High glucocorticoid receptor affinity



**Low systemic bioavailability**  
Minimizes systemic effects

+ Not all steroids are created equal

Topical Corticosteroid	Brand Name Examples	Modes of Topical Sinonasal Delivery	Lipophilicity <sup>4*</sup>	Glucocorticoid Potency <sup>5†</sup> (Receptor Affinity)	Systemic Bioavailability <sup>6‡</sup>
Dexamethasone	Decadron <sup>®</sup>	Injectable applied to nasal dressing	Very Low (<1.0) <sup>7</sup>	Very Low (100)	High (76%)
Triamcinolone acetonide	Kenalog <sup>®</sup> , Nasacort <sup>®</sup> AQ	Injectable applied to nasal dressing, spray	Low (1.0)	Low (233)	Medium (46%)
Budesonide	Rhinocort <sup>®</sup> Aqua, Pulmicort <sup>®</sup>	Spray, respules mixed with saline for irrigation	Low (1.6)	Intermediate (935)	Medium (34%)
Fluticasone propionate	Flonase <sup>®</sup>	Spray	High (12.6)	High (1800)	Very Low (<1.0)
<b>Mometasone furoate</b>	<b>Nasonex<sup>®</sup>, PROPEL<sup>®</sup></b>	<b>Spray, Steroid Eluting Sinus Implant</b>	<b>High (20.0)</b>	<b>High (2300)</b>	<b>Very Low (&lt;1%)</b>

+ PROPEL provides localized and effective drug delivery

## 30 DAYS

### DRUG DELIVERY

Gradual release of 370 µg of mometasone furoate directly to sinus mucosa

## 60 DAYS

### DRUG IN TISSUE

Mometasone furoate is present in mucosal tissue<sup>8§</sup>

## 180 DAYS

### SYMPTOM IMPROVEMENT

Significant improvement in symptoms after surgery<sup>9</sup>

+ Why PROPEL is right for your patients

The PROPEL family of implants release mometasone furoate and have been shown to reduce inflammation and scarring leading to a **reduction in the need for postoperative surgical and/or oral steroid interventions**

\*Lipophilicity numbers normalized relative to triamcinolone acetonide. <sup>†</sup>As measured by relative receptor binding affinity compared to dexamethasone, which is set to a value of 100. Higher values designate greater potency. <sup>‡</sup>As measured by plasma concentration of drug from intranasal vs intravenous route. <sup>§</sup>Pre-clinical animal data.

The PROPEL sinus implants are indicated to maintain patency and locally deliver steroid to the sinus mucosa in patients ≥18 years of age after sinus surgery: PROPEL for the ethmoid sinus, PROPEL Mini for the ethmoid sinus/frontal sinus opening, and PROPEL Contour for the frontal/maxillary sinus ostia.

Contraindications include patients with intolerance to mometasone furoate (MF) or hypersensitivity to bioabsorbable polymers. Safety and effectiveness of the implant in pregnant or nursing females have not been studied. Risks may include, but are not limited to, pain/pressure, displacement of the implant, possible side effects of intranasal MF, sinusitis, epistaxis, and infection.

For full prescribing information see IFU at [www.IntersectENT.com/technologies/](http://www.IntersectENT.com/technologies/). Rx only.

INTERSECT ENT and PROPEL are registered trademarks of Intersect ENT, Inc. in the United States and other countries.

©2019 Intersect ENT, Inc. All rights reserved. MPM-11669 Rev. 1.0

**References:** **1.** PROPEL Instructions for Use. Menlo Park, CA: Intersect ENT; 2013. **2.** PROPEL Mini Instructions for Use. Menlo Park, CA: Intersect ENT; 2016. **3.** PROPEL Contour Instructions for Use. Menlo Park, CA: Intersect ENT; 2016. **4.** Lemke T, et al. *Foye's Principles of Medicinal Chemistry*. 2008. **5.** Winkler J, et al. *Proc Am Thorac Soc*. 2004;1(4): 356-363. **6.** Sastre J, et al. *J Investig Allergol Clin Immunol*. 2012;22(1):1-12. **7.** PubChem. Dexamethasone. <https://pubchem.ncbi.nlm.nih.gov/compound/Dexamethasone>. Accessed October 22, 2019. **8.** Li PM, et al. *Am J Rhinol Allergy*. 2009;23(6):591-596. **9.** Fowith K, et al. *Laryngoscope*. 2011;121(11):2473-2480.

